Skip to main content
Clinical Trials/JPRN-UMIN000003970
JPRN-UMIN000003970
Recruiting
Phase 1

Phase I/II study of photodynamic therapy (PDT) using talaporfin sodium and diode laser for local failure after chemoradiotherapy (CRT) or radiotherapy (RT) for patients with esophageal cancer - Phase I/II study of PDT using talaporfin sodium and diode laser after CRT for esophageal cancer

Kyoto University0 sites28 target enrollmentOctober 1, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Esophageal cancer
Sponsor
Kyoto University
Enrollment
28
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2010
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Phase I 1\) severe complication as follows; uncontrollable hypertension, uncontrollable diabetes mellitus, severe liver cirrhosis, severe cardiovascular disease (myocardial infarction, angina pectoris, congestive heart failure) 2\) systemic infection 3\) inability to keep sun shade 4\) additional PDT just after salvage EMR for local failure after CRT or RT 5\) baseline T4 to Aorta 6\) known porphyria 7\) photosensitive disorder 8\) prior PDT using talaporfin sodium, prior PDT using porfimer sodium within 3 months. 9\) woman during pregnancy or breast\-feeding, patient who refuse to prevent pregnancy 10\) patient judged as inadequate to entry by each investigator Phase II 1\) other active malignancies except for early gastrointestinal cancer curable with endoscopic treatment 2\) severe complication as follows; uncontrollable hypertension, uncontrollable diabetes mellitus, severe liver cirrhosis, severe cardiovascular disease (myocardial infarction, angina pectoris, congestive heart failure) 3\) systemic infection 4\) inability to keep sun shade 5\) additional PDT just after salvage EMR for local failure after CRT or RT 6\) baseline T4 to Aorta 7\) known porphyria 8\) photosensitive disorder 9\) prior PDT using talaporfin sodium or porfimer sodium. 10\) woman during pregnancy or breast\-feeding, patient who refuse to prevent pregnancy 11\) patient judged as inadequate to entry by each investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials